Re­Code rais­es an­oth­er $50M; His­to­gen halts clin­i­cal de­vel­op­ment; 60 De­grees with­draws Covid-19 IND

Re­Code Ther­a­peu­tics is back with an ad­di­tion­al $50 mil­lion more than a year af­ter it raised $120 mil­lion.

The Men­lo Park, CA-based biotech is de­vel­op­ing new mR­NA treat­ments, and the key, it be­lieves, is the de­liv­ery sys­tem. Re­Code’s plat­form en­gi­neers lipid nanopar­ti­cles — the fat­ty acid cap­sules used in Mod­er­na and BioN­Tech/Pfiz­er’s Covid-19 vac­cines.

Re­Code’s lat­est se­ries B raise in­clud­ed two new in­vestors: Bi­o­lu­mi­nes­cence Ven­tures and So­las­ta Ven­tures, the com­pa­ny said Tues­day morn­ing. Kou­ki Ha­rasa­ki, Bi­o­lu­mi­nes­cence’s found­ing part­ner and for­mer­ly of Mi­crosoft Ven­tures and a16z, joined Re­Code’s board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER